Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
09 01 2023
Historique:
received: 01 06 2022
revised: 03 08 2022
accepted: 04 10 2022
pubmed: 11 10 2022
medline: 11 1 2023
entrez: 10 10 2022
Statut: ppublish

Résumé

Many colorectal cancer-related procedures were suspended during the COVID-19 pandemic. In this study, we predict the impact of resulting delays in screening (colonoscopy, FIT, and sigmoidoscopy) and diagnosis on colorectal cancer-related outcomes, and compare different recovery scenarios. Using the MISCAN-Colon model, we simulated the US population and evaluated different impact and recovery scenarios. Scenarios were defined by the duration and severity of the disruption (percentage of eligible adults affected), the length of delays, and the duration of the recovery. During recovery (6, 12 or 24 months), capacity was increased to catch up missed procedures. Primary outcomes were excess colorectal cancer cases and -related deaths, and additional colonoscopies required during recovery. With a 24-month recovery, the model predicted that the US population would develop 7,210 (0.18%) excess colorectal cancer cases during 2020-2040, and 6,950 (0.65%) excess colorectal cancer-related deaths, and require 108,500 (8.6%) additional colonoscopies per recovery month, compared with a no-disruption scenario. Shorter recovery periods of 6 and 12 months, respectively, decreased excess colorectal cancer-related deaths to 4,190 (0.39%) and 4,580 (0.43%), at the expense of 260,200-590,100 (20.7%-47.0%) additional colonoscopies per month. The COVID-19 pandemic will likely cause more than 4,000 excess colorectal cancer-related deaths in the US, which could increase to more than 7,000 if recovery periods are longer. Our results highlight that catching-up colorectal cancer-related services within 12 months provides a good balance between required resources and mitigation of the impact of the disruption on colorectal cancer-related deaths.

Sections du résumé

BACKGROUND
Many colorectal cancer-related procedures were suspended during the COVID-19 pandemic. In this study, we predict the impact of resulting delays in screening (colonoscopy, FIT, and sigmoidoscopy) and diagnosis on colorectal cancer-related outcomes, and compare different recovery scenarios.
METHODS
Using the MISCAN-Colon model, we simulated the US population and evaluated different impact and recovery scenarios. Scenarios were defined by the duration and severity of the disruption (percentage of eligible adults affected), the length of delays, and the duration of the recovery. During recovery (6, 12 or 24 months), capacity was increased to catch up missed procedures. Primary outcomes were excess colorectal cancer cases and -related deaths, and additional colonoscopies required during recovery.
RESULTS
With a 24-month recovery, the model predicted that the US population would develop 7,210 (0.18%) excess colorectal cancer cases during 2020-2040, and 6,950 (0.65%) excess colorectal cancer-related deaths, and require 108,500 (8.6%) additional colonoscopies per recovery month, compared with a no-disruption scenario. Shorter recovery periods of 6 and 12 months, respectively, decreased excess colorectal cancer-related deaths to 4,190 (0.39%) and 4,580 (0.43%), at the expense of 260,200-590,100 (20.7%-47.0%) additional colonoscopies per month.
CONCLUSIONS
The COVID-19 pandemic will likely cause more than 4,000 excess colorectal cancer-related deaths in the US, which could increase to more than 7,000 if recovery periods are longer.
IMPACT
Our results highlight that catching-up colorectal cancer-related services within 12 months provides a good balance between required resources and mitigation of the impact of the disruption on colorectal cancer-related deaths.

Identifiants

pubmed: 36215205
pii: 709686
doi: 10.1158/1055-9965.EPI-22-0544
pmc: PMC9827109
mid: NIHMS1842726
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

22-29

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA199335
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA253913
Pays : United States

Informations de copyright

©2022 The Authors; Published by the American Association for Cancer Research.

Références

Science. 2020 Jun 19;368(6497):1290
pubmed: 32554570
Comput Biomed Res. 1999 Feb;32(1):13-33
pubmed: 10066353
Cancer. 2022 Mar 1;128(5):1048-1056
pubmed: 34866184
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1445-1451.e8
pubmed: 27211498
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
JCO Clin Cancer Inform. 2020 Jul;4:657-665
pubmed: 32716647
Am J Gastroenterol. 2021 Feb 1;116(2):433-434
pubmed: 33038127
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1410-1417.e9
pubmed: 32898707
Gastroenterology. 2018 Nov;155(5):1383-1391.e5
pubmed: 30031768
J Med Screen. 2021 Jun;28(2):100-107
pubmed: 33241760
Gastroenterology. 2021 Mar;160(4):1400-1402.e1
pubmed: 33301778
Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164
pubmed: 29150480
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
JAMA Netw Open. 2021 Apr 1;4(4):e216454
pubmed: 33843997
Tech Innov Gastrointest Endosc. 2021;23(4):313-321
pubmed: 34345871
Gastroenterology. 2021 Mar;160(4):999-1002
pubmed: 33096099
Gastroenterology. 2012 Sep;143(3):844-857
pubmed: 22763141
Ann Intern Med. 1999 Mar 16;130(6):525-30
pubmed: 10075621
Cancer. 2016 Aug 15;122(16):2479-86
pubmed: 27200481
JCO Clin Cancer Inform. 2020 Nov;4:1059-1071
pubmed: 33253013
JAMA Oncol. 2021 Jun 1;7(6):878-884
pubmed: 33914015
Gastroenterology. 2022 Sep;163(3):723-731.e6
pubmed: 35580655
Cancer. 2020 Sep 1;126(17):3894-3895
pubmed: 32776530
Ann Intern Med. 2014 Jun 3;160(11):750-9
pubmed: 24887616
Future Oncol. 2020 Sep;16(25):1879-1881
pubmed: 32564611
JAMA. 2021 May 18;325(19):1998-2011
pubmed: 34003219

Auteurs

Rosita van den Puttelaar (R)

Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.

Iris Lansdorp-Vogelaar (I)

Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.

Anne I Hahn (AI)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Carolyn M Rutter (CM)

RAND Corporation, Santa Monica, California.

Theodore R Levin (TR)

Department of Gastroenterology, Kaiser Permanente Medical Center, Walnut Creek, California.

Ann G Zauber (AG)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.

Reinier G S Meester (RGS)

Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH